Features Associated With Weight Loss and Growth Stunting for Young Children During Cancer Therapy

• Authors: Daniel Runco, Indiana University; Karen Wasilewski-Masker, Emory University; Claire Mazewski, Emory University; Briana Patterson, Emory University; Ann Mertens, Emory University
• Journal Title: JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
• Volume: Volume 43, Number 8
• Publisher: LIPPINCOTT WILLIAMS & WILKINS | 2021-11-01, Pages 301-307
• Type of Work: Article | Post-print: After Peer Review
• Publisher DOI: http://doi.org/10.1097/MPH.0000000000002246
• Subjects: Health Sciences, Oncology
• Keywords: Science & Technology; Life Sciences & Biomedicine; Oncology; Hematology; Pediatrics; cancer; nutrition; pediatric oncology; cancer cachexia; infant; GUIDELINES NUTRITION SUPPORT; ACUTE LYMPHOBLASTIC-LEUKEMIA; PEDIATRIC-PATIENTS; ENTERAL NUTRITION; DIETETICS/AMERICAN SOCIETY; CONSENSUS STATEMENT; MALNUTRITION; ONCOLOGY; MEDULLOBLASTOMA; ACADEMY

Abstract

Features associated with malnutrition are poorly elucidated in pediatric cancer care. We aimed to better understand characteristics associated with weight-for-height (WHZ) and height-for-age (HAZ) changes for infants and young children during cancer treatment. This retrospective study included 434 patients diagnosed <3 years old from 2007 to 2015 at a large pediatric cancer center. Patients starting treatment outside our center, those with relapsed or secondary malignancies, or with inaccurate information were excluded. Abstracted weights and heights for a 24-month period after treatment initiation were converted to sex-specific and age-specific z scores. Although not statistically different at baseline, patients with hematologic malignancies gained weight over time, while other tumor types did not. Higher treatment intensity and younger age at diagnosis increased odds of clinically significant weight loss. Older children had higher HAZ at diagnosis and HAZ also significantly decreased over time for all examined risk factors, which is distinctly different from patterns in WHZ over time. In conclusion, WHZ and HAZ are affected differently by cancer treatment in infants and young children. We identify key risk factors for weight loss and growth stunting which will be necessary to develop prospective trials to examine anthropometric, biochemical, and patient recorded outcomes around nutrition.